Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Avian Influenza
Interventions: AS03, MF59, Monovalent Influenza A/H5N8 vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more

Conditions: Neoplasms
Interventions: trivalent influenza vaccine; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: CSL's 2009 H1N1 Influenza Vaccine (CSL425), Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 6 Months to 9 Years
Enrollment: 473 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: Chandler, Arizona • Melbourne, Florida • Bardstown, Kentucky + 10 more

Conditions: H1N1 Influenza, Seasonal Influenza
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 12 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: Not listed
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Easley, South Carolina

Conditions: Influenza
Interventions: 2016-2017 Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 20 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 3, Quadrivalent RIV with H3 strain 4, Quadrivalent RIV with 2018-2019 NH H3 strain; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Hollywood, Florida • Rochester, New York • North Charleston, South Carolina

Conditions: Influenza, Human
Interventions: Seasonal influenza vaccine; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 99 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Inflammatory Bowel Disease (IBD), Immunosuppressed or Non-Immunosuppressed, Influenza Vaccine, Antibody Titers, Seroprotective Titers
Interventions: blood draw; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, Influenza
Interventions: Lucira COVID-19 & Flu Test; Device
Lead sponsor: Lucira Health Inc; Industry
Eligibility: 2 Years and older
Enrollment: 1,361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Cullman, Alabama • Colton, California • Oakland, California + 4 more

Conditions: Healthy
Interventions: Seasonal Inactivated Influenza Vaccine; Biological
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm, Viral Infection
Interventions: cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Influenza, Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions: Risk Reduction; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40,671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Influenza
Interventions: Alert, Salient alert features, High-risk Text, Risk factors; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80,452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Influenza
Interventions: CAIV-T or TIV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 2
States / cities: New Port Richey, Florida • Charlottesville, Virginia

Conditions: Influenza Vaccination
Interventions: Influenza vaccination; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 9,172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 96
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 86 more

Conditions: Influenza, Human
Interventions: FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 833 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more

Conditions: Flu-like Symptoms
Interventions: Not listed
Lead sponsor: Christine Hunter; Other
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Influenza Donor Visit, Influenza Recipient Inpatient Exposures Sessions; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
Interventions: VRC-AVIDNA036-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

COVID-19 Coagulopathy Extension Study

Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine

Performance Evaluation of the Lucira COVID-19 & Flu Test

Immune and Hormone Response to Influenza Vaccine

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications

High-risk Influenza Vaccine Alert

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

Study of Immune Responses to Influenza Vaccination

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Flu-Like Symptoms as a Complication of Botulinum Toxin Therapy

A Human Influenza Transmission Study Using Naturally Infected Community Donors

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally